Light Therapy for Autism
(TPBMASD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special headband that shines infrared light on the heads of children aged 2 to 6 with moderate to severe autism. The light may help improve brain function and reduce autism symptoms.
Will I have to stop taking my current medications?
Yes, participants must stop taking any psychotropic medications (drugs that affect mood, perception, or behavior) before joining the trial.
Is light therapy, also known as Cognilum TM, safe for humans?
How does the treatment Cognilum TM differ from other treatments for autism?
Cognilum TM, involving light therapy, is unique because it uses transcranial photobiomodulation (tPBM), which involves applying red to near-infrared light to the brain to improve brain function and reduce autism symptoms. Unlike traditional treatments, it is non-pharmacological and focuses on enhancing brain connectivity and reducing inflammation, offering a novel approach for managing autism.678910
What data supports the effectiveness of the treatment Cognilum TM for autism?
Research on photobiomodulation, a therapy using red to near-infrared light, shows it may help improve brain function and reduce symptoms in autism, such as social difficulties and repetitive behaviors. A study found that 50% of adults with autism who received this light therapy showed significant improvement in social responsiveness and overall functioning.6791112
Who Is on the Research Team?
Yuli Fradkin, MD
Principal Investigator
RDT Group NJ
Are You a Good Fit for This Trial?
This trial is for children aged 2-6 with moderate to severe autism. They can participate even if they have another psychiatric disorder, as long as it's not excluded, and are allowed to continue behavioral therapies during the study. Parents must understand the study and consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Transcranial photobiomodulation is administered twice a week for 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cognilum TM
Find a Clinic Near You
Who Is Running the Clinical Trial?
JelikaLite LLC
Lead Sponsor